Michael Maitland
University of Chicago Comprehensive Cancer Center · The University of Chicago Medical Center · University of Chicago
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Maitland as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:34 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT01122888 · Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma MultiformeNational Cancer Institute (NCI) · terminated · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
- N/ANCT01063283 · Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLCUniversity of Chicago · completed · Advanced Non-squamous Non-Small Cell Lung Cancer · principal investigator
- N/ANCT00607477 · Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced HypertensionUniversity of Chicago · terminated · Treatment Induced Hypertension · principal investigator
- Ph2NCT00472771 · INNO-206 in Patients With Small Cell Lung Cancer (SCLC)CytRx · withdrawn · Small Cell Lung Cancer · principal investigator
- Ph1NCT00436579 · Sorafenib in Treating Patients With Advanced Solid TumorsNational Cancer Institute (NCI) · terminated · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
- Ph2NCT00203931 · Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung CancerUniversity of Chicago · terminated · Non-small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical TherapeuticsT32GM007019 · NIGMS · UNIVERSITY OF CHICAGO · fiscal years 2015 · $410,223 awarded in 2015Same name and institution; not confirmed by an ID
- Experimental Therapeutics: Clinical Trials Network with Phase I EmphasisUM1CA186705 · NCI · UNIVERSITY OF CHICAGO · fiscal years 2014 to 2015 · $476,528 awarded in 2015Same name and institution; not confirmed by an ID
- Translational Medicine and Cancer Therapy with Vasculature-Targeted AgentsK23CA124802 · NCI · UNIVERSITY OF CHICAGO · fiscal years 2007 to 2011 · $129,843 awarded in 2011Same name and institution; not confirmed by an ID
- A STUDY OF SORAFENIB (BAY 43-9006) AND BLOOD PRESSUREM01RR000055 · NCRR · UNIVERSITY OF CHICAGO · fiscal years 2007 · $64,570 awarded in 2007Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Clinical and Experimental TherapeuticsP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI Wendy Stock · fiscal years 2010 to 2026Named on NCT01122888, NCT00436579
- Phase I Clinical Trials of Anti-Cancer AgentsU01CA069852 · NCI · UNIVERSITY OF CHICAGO · PI MARK J RATAIN · fiscal years 2010 to 2013Named on NCT01122888, NCT00436579
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in glioblastoma.